1032825-55-0

Basic information

• Product Name: 4-[1-[(Methylsulfonyl)oxy]ethyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester
• Synonyms: 4-[1-[(Methylsulfonyl)oxy]ethyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester;tert-butyl 4-(1-(methylsulfonyloxy)ethyl)piperidine-1-carboxylate
• CAS NO: 1032825-55-0
• Molecular Weight: 307.411
• Mol File: 1032825-55-0.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 4-[1-[(Methylsulfonyl)oxy]ethyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[1-[(Methylsulfonyl)oxy]ethyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester(1032825-55-0)
• EPA Substance Registry System: 4-[1-[(Methylsulfonyl)oxy]ethyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester(1032825-55-0)

Safety Data

• Hazardous Substances Data: 1032825-55-0(Hazardous Substances Data)

Upstream product

• 183170-69-6 1-tert-Butyloxycarbonyl-4-hydroxyethyl-piperidine 
• 6457-48-3 4-(1-hydroxyethyl)piperidine 
• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 206989-61-9 4-acetyl-1-(t-butoxycarbonyl)piperidine 
• 124-63-0 methanesulfonyl chloride 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1138331-68-6 tert-butyl 4-(1-((3-(trifluoromethyl)phenyl)thio)ethyl)piperidine-1-carboxylate 
• 1262399-79-0 4-{1-[4-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-phenoxy]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 1138327-90-8 1-[4-(methylsulfonyl)-2-(trifluoromethoxy)benzoyl]-4-(1-([3-(trifluoromethyl)phenyl]sulfonyl)ethyl)piperidine 
• 1138328-15-0 (4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)(4-(2-((3-(trifluoromethyl)phenyl)sulfonyl)propan-2-yl)piperidin-1-yl)methanone 
• 1138328-17-2 1-[5-fluoro-2-(methylsulfonyl)benzoyl]-4-(1-methyl-1-([3-(trifluoromethyl)phenyl]sulfonyl)ethyl)piperidine 
• 1138327-98-6 tert-butyl 4-(1-{[3-(trifluoromethyl)phenyl]sulfonyl}ethyl)piperidine-1-carboxylate 
• 1138331-69-7 tert-butyl 4-(1-methyl-1-{[3-(trifluoromethyl)phenyl]sulfonyl}ethyl)piperidine-1-carboxylate 

Relevant articles and documents

Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2 H-benzo[ b][1,4]oxazin-6-yl Moiety

The therapeutic potential of monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases has attracted attention worldwide. However, the availability of reversible-type inhibitor is still limited to clarify the pharmacological eff

MUSCARINIC AGONISTS

This invention relates to compounds that are agonists of the muscarinic receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a) or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.

Improved Cav2.2 channel inhibitors through a gem -dimethylsulfone bioisostere replacement of a labile sulfonamide

We report the investigation of sulfonamide-derived Cav2.2 inhibitors to address drug-metabolism liabilities with this lead class of analgesics. Modification of the benzamide substituent provided improvements in both potency and selectivity. However, we discovered that formation of the persistent 3-(trifluoromethyl)benzenesulfonamide metabolite was an endemic problem in the sulfonamide series and that the replacement of the center aminopiperidine scaffold failed to prevent this metabolic pathway. This issue was eventually addressed by application of a bioisostere strategy. The new gem-dimethyl sulfone series retained Cav2.2 potency without the liability of the circulating sulfonamide metabolite.